Among the drugs that can be administered to patients with non-hemodialysis CKD are ACE inhibitors, which have cardiorenal protection properties that have been shown to reduce adverse cardiovascular and renal events, and all-cause mortality in stage 3–5 non-dialysis CKD patients [68]. This evidence concerns the gene ACE and chronic kidney disease.